Clinical Trial Update: FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating FOLFOX plus regorafenib in unresectable or metastatic esophagogastric cancer has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• FOLFOX
• Regorafenib (regorafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-05-15